Metrics of Pure Play Diagnostic Companies: Comparison to GenProbe

follow url M&A Premium of Diagnostic Companies

Bloomberg reported on April 29 that GenProbe (GPRO) was seeking a buyer. We reported earlier this month on the M&A trend in biotechnology, tools and diagnostics and we will begin following the sector looking for value and potential buy-out targets.

Here is our preliminary list of pure play operating diagnostic companies. Any comments on this analysis are welcome.

Company Ticker Price Rev.est/Yr Q1Rev Marketcap P/S PE SE
5/18/11 $M $M est $M
buy modafinil in london GenProbe http://ezeta.com/index.php?option=com_content GPRO 80 582 143 3800 6.53 36.8 822
Abaxis ABAX 28 163 37.5 633 3.9 44 163
Cepheid CPHD 30.5 255 60.2 1888 7.4 N/A 167
GenomicHealth GHDX 25.85 208.9 49.8 756 2.96 132 91.8
Immucor BLUD 20.3 330 83.3 1430 4.33 16.5 537
Luminex LMNX 20 168.4 43.3 840.95 5 111 240
Meridian VIVO 23.4 166 41 959.5 5.78 38.4 137.6
Neogen NEOG 40.6 173 42.2 941 5.44 44.6 178.4
Qiagen QGEN 20 1160 264 4700 4.05 34.6 2536
Quidel QDEL 14.55 162.6 59.6 482 2.96 148 183.4
SeraCare SRLS 3.7 46.9 11 71 1.51 10.3 38
Techne TECH 80.5 285.9 76.3 3000 10.5 27.3 566.3

P/S is Price to Sales based on current fiscal year estimates. SE is stockholder equity or book value.

No comments yet.

Leave a Reply